Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
Alexa Thibodeau, Nambi Nallasamy Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USACorrespondence: Nambi NallasamyDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-10-01
|
| Series: | International Medical Case Reports Journal |
| Subjects: | |
| Online Access: | https://www.dovepress.com/bilateral-anterior-subcapsular-cataract-development-following-initiati-peer-reviewed-fulltext-article-IMCRJ |
| _version_ | 1819104473878888448 |
|---|---|
| author | Thibodeau A Nallasamy N |
| author_facet | Thibodeau A Nallasamy N |
| author_sort | Thibodeau A |
| collection | DOAJ |
| description | Alexa Thibodeau, Nambi Nallasamy Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USACorrespondence: Nambi NallasamyDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, 48105, USATel +1 734 763 5506Fax +1 734 936 2340Email nnallasa@med.umich.eduAbstract: Enfortumab vedotin is an antibody–drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient’s presentation may reflect the first report of an undocumented adverse effect of this novel agent.Keywords: anterior subcapsular cataract, enfortumab vedotin, urothelial carcinoma |
| first_indexed | 2024-12-22T02:06:55Z |
| format | Article |
| id | doaj.art-a0fc639658174164897709a72b27391a |
| institution | Directory Open Access Journal |
| issn | 1179-142X |
| language | English |
| last_indexed | 2024-12-22T02:06:55Z |
| publishDate | 2021-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Medical Case Reports Journal |
| spelling | doaj.art-a0fc639658174164897709a72b27391a2022-12-21T18:42:31ZengDove Medical PressInternational Medical Case Reports Journal1179-142X2021-10-01Volume 1470770969339Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab VedotinThibodeau ANallasamy NAlexa Thibodeau, Nambi Nallasamy Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USACorrespondence: Nambi NallasamyDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, 48105, USATel +1 734 763 5506Fax +1 734 936 2340Email nnallasa@med.umich.eduAbstract: Enfortumab vedotin is an antibody–drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient’s presentation may reflect the first report of an undocumented adverse effect of this novel agent.Keywords: anterior subcapsular cataract, enfortumab vedotin, urothelial carcinomahttps://www.dovepress.com/bilateral-anterior-subcapsular-cataract-development-following-initiati-peer-reviewed-fulltext-article-IMCRJanterior subcapsular cataractenfortumab vedotinurothelial carcinoma |
| spellingShingle | Thibodeau A Nallasamy N Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin International Medical Case Reports Journal anterior subcapsular cataract enfortumab vedotin urothelial carcinoma |
| title | Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin |
| title_full | Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin |
| title_fullStr | Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin |
| title_full_unstemmed | Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin |
| title_short | Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin |
| title_sort | bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin |
| topic | anterior subcapsular cataract enfortumab vedotin urothelial carcinoma |
| url | https://www.dovepress.com/bilateral-anterior-subcapsular-cataract-development-following-initiati-peer-reviewed-fulltext-article-IMCRJ |
| work_keys_str_mv | AT thibodeaua bilateralanteriorsubcapsularcataractdevelopmentfollowinginitiationofenfortumabvedotin AT nallasamyn bilateralanteriorsubcapsularcataractdevelopmentfollowinginitiationofenfortumabvedotin |